Inavolisib + Palbociclib-Fulvestrant Improves Survival in Advanced Breast Cancer

THURSDAY, Oct. 31, 2024-- Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth...